A phase 1 study of RPT 2950
Latest Information Update: 22 Sep 2023
At a glance
- Drugs RPT-2950 (Primary)
- Indications Autoimmune disorders
- Focus Adverse reactions
Most Recent Events
- 22 Sep 2023 New trial record
Latest Information Update: 22 Sep 2023